Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
Palisade Bio (NASDAQ: PALI) has initiated its Phase 1 clinical study of PALI-2108, dosing its first subject. The study evaluates an orally administered PDE4 inhibitor prodrug for treating moderate-to-severe Ulcerative Colitis (UC). The single-center, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and UC patients. The study includes single ascending dose (SAD) cohorts, food effect evaluation, multiple ascending dose (MAD) cohorts, and a UC patient cohort. Topline data is expected in first half of 2025.
Palisade Bio (NASDAQ: PALI) ha avviato il suo studio clinico di Fase 1 su PALI-2108, somministrando la prima dose a un soggetto. Lo studio valuta un profarmaco inibitore PDE4 somministrato per via orale per il trattamento della Colite Ulcerosa (UC) di moderata-grave intensità. Questo studio a centro singolo, in doppio cieco e controllato con placebo, valuterà la sicurezza, la tollerabilità, la farmacocinetica e la farmacodinamica sia in volontari sani che in pazienti con UC. Lo studio include coorti a dose ascendenti singole (SAD), valutazione dell'effetto alimentare, coorti a dosi ascendenti multiple (MAD) e una coorte di pazienti UC. I dati preliminari sono attesi nella prima metà del 2025.
Palisade Bio (NASDAQ: PALI) ha iniciado su estudio clínico de Fase 1 sobre PALI-2108, administrando la primera dosis a un sujeto. El estudio evalúa un profármaco inhibidor de PDE4 que se toma por vía oral para el tratamiento de la Colitis Ulcerosa (UC) moderada a severa. Este es un estudio de un solo centro, doble ciego y controlado con placebo que evaluará la seguridad, la tolerabilidad, la farmacocinética y la farmacodinamia tanto en voluntarios sanos como en pacientes con UC. El estudio incluye cohortes de dosis ascendentes individuales (SAD), evaluación del efecto de los alimentos, cohortes de dosis ascendentes múltiples (MAD) y una cohorte de pacientes con UC. Se esperan datos preliminares para la primera mitad de 2025.
Palisade Bio (NASDAQ: PALI)는 PALI-2108의 1상 임상 연구를 시작하였으며, 첫 번째 피험자에게 투여하였습니다. 이 연구는 중증도에서 심각한 궤양성 대장염(UC) 치료를 위한 구강 투여 PDE4 억제자 프로드럭을 평가합니다. 이 단일 센터, 이중 맹검, 위약 대조 연구는 건강한 자원봉사자와 UC 환자 모두에 대한 안전성, 내약성, 약동학 및 약력학을 평가할 것입니다. 연구에는 단일 상승 용량(SAD) 코호트, 음식 효과 평가, 다중 상승 용량(MAD) 코호트 및 UC 환자 코호트가 포함됩니다. 주요 데이터는 2025년 상반기에 예상됩니다.
Palisade Bio (NASDAQ: PALI) a lancé son étude clinique de Phase 1 sur PALI-2108, administrant la première dose à un sujet. L'étude évalue un pro-médicament inhibiteur de la PDE4 administré par voie orale pour le traitement de la Colite Ulcéreuse (UC) modérée à sévère. Cette étude à centre unique, en double aveugle et contrôlée par placebo, évaluera la sécurité, la tolérance, la pharmacocinétique et la pharmacodynamique tant chez des volontaires sains que chez des patients atteints d'UC. L'étude comprend des cohortes à dose unique croissante (SAD), une évaluation de l'effet des aliments, des cohortes à doses multiples croissantes (MAD) et une cohorte de patients UC. Les résultats préliminaires sont attendus au cours de la première moitié de 2025.
Palisade Bio (NASDAQ: PALI) hat seine Phase-1-Studie zu PALI-2108 initiiert und den ersten Probanden dosiert. Die Studie bewertet ein oral verabreichtes PDE4-Inhibitor-Prodrug zur Behandlung von mittelschwerer bis schwerer Colitis ulcerosa (UC). Die Einzelzentrum-Studie in doppelter Blindstudie und Placebo-kontrolliert wird Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik sowohl bei gesunden Probanden als auch bei UC-Patienten bewerten. Die Studie umfasst Einzel-Dosis-steigerungs-Kohorten (SAD), eine Bewertung des Nahrungsmittel-Effekts, Mehrfach-Dosis-steigerungs-Kohorten (MAD) und eine Kohorte von UC-Patienten. Die ersten Daten werden in der ersten Jahreshälfte 2025 erwartet.
- First subject dosed in Phase 1 clinical trial, marking transition to clinical stage company
- Comprehensive study design including both healthy volunteers and UC patients
- Clear timeline for topline data release in H1 2025
- PALI-2108 is a new chemical entity never tested in humans before, increasing development risk
Insights
The initiation of Phase 1 clinical trials for PALI-2108 represents a significant milestone for Palisade Bio. The study's comprehensive design, incorporating both healthy volunteers and UC patients, will provide important safety and efficacy data for this novel PDE4 inhibitor prodrug. The trial's focus on local bioactivation in the colon is particularly noteworthy, as it may potentially reduce systemic side effects common to other PDE4 inhibitors.
The inclusion of multiple biomarkers (hsCRP, CalPro) and tissue analysis will provide valuable mechanistic insights. The MAD and SAD cohorts, combined with food effect studies, will establish a thorough pharmacological profile. While this is an early-stage trial, the established success of other PDE4 inhibitors in inflammatory conditions provides a promising backdrop for PALI-2108's development. However, investors should note that topline data expected in H1 2025 means significant time before potential commercialization.
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that is locally bioactivated in the colon and is in development for patients affected by UC.
The Phase 1 study will evaluate PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, alongside an open-label study involving a patient cohort with UC. Patient screening for the study is underway.
“The dosing of our first subject marks an important milestone as Palisade transitions to a clinical stage company. We anticipate releasing topline data during the first half of 2025,” commented JD Finley, Chief Executive Officer of Palisade Bio.
The primary aim of this single-center Phase 1 study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of PALI-2108 in healthy volunteers as well as to evaluate the safety, tolerability, and pharmacokinetics (PK), and pharmacodynamics (PD) in patients with UC. Several PDE4 inhibitors have received market approval in both inflammatory and fibrotic disease; however, PALI-2108 represents a new chemical entity that has not been previously administered to humans. The study will consist of single ascending dose (SAD) cohorts followed by a crossover study to evaluate the effects of food on PK, followed by multiple ascending dose (MAD) cohorts, and finally a multiple dose cohort of patients with UC. Comprehensive safety monitoring and similar PK evaluations will be conducted in this cohort. Biomarkers, including serum high sensitivity C-reactive protein (hsCRP), and fecal calprotectin (CalPro), along with colonic tissue histological assessments, will be employed to provide further insights into the drug's effects. The analysis of colon tissue will include the study drug and metabolite levels, PDE4 expression, cyclic adenosine monophosphate (cAMP) levels, Absolute Lymphocyte Count (ALC), and related PD biomarkers, which are crucial for understanding the drug's mechanism and efficacy.
For more information about the Phase 1 clinical study, visit clinicaltrials.gov and reference identifier NCT06663605.
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and most recent Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on March 26, 2024 and August 12, 2024, respectively. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What is the purpose of Palisade Bio's Phase 1 trial for PALI-2108?
When will Palisade Bio (PALI) release topline data for the PALI-2108 Phase 1 trial?